IDMC recommends discontinuation of Phase III CRPC trial of ProstVac

Bavarian Nordic A/S (CSE:BAVA) said an IDMC recommended discontinuing for futility the Phase III PROSPECT trial of ProstVac rilimogene galvacirepvec to treat metastatic castration-resistant prostate cancer based on a preplanned interim analysis.

The primary endpoint of the double-blind, placebo-controlled trial is overall survival (OS). Bavarian Nordic has an SPA from FDA for the trial, which enrolled 1,297 asymptomatic or minimally symptomatic metastatic CRPC patients to receive ProstVac alone or in combination with GM-CSF...